Histone deacetylases (HDAC) in physiological and pathological bone remodelling

Cantley, M. D., Zannettino, A. C. W., Bartold, P. M., Fairlie, D. P. and Haynes, D. R. (2017) Histone deacetylases (HDAC) in physiological and pathological bone remodelling. Bone, 95 162-174. doi:10.1016/j.bone.2016.11.028

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads

Author Cantley, M. D.
Zannettino, A. C. W.
Bartold, P. M.
Fairlie, D. P.
Haynes, D. R.
Title Histone deacetylases (HDAC) in physiological and pathological bone remodelling
Journal name Bone   Check publisher's open access policy
ISSN 8756-3282
Publication date 2017-02-01
Year available 2016
Sub-type Critical review of research, literature review, critical commentary
DOI 10.1016/j.bone.2016.11.028
Open Access Status File (Author Post-print)
Volume 95
Start page 162
End page 174
Total pages 13
Place of publication Philadelphia, PA, United States
Publisher Elsevier
Language eng
Formatted abstract
Histone deacetylases (HDACs)2 play important roles in the epigenetic regulation of gene expression in cells and are emerging therapeutic targets for treating a wide range of diseases. HDAC inhibitors (HDACi)3 that act on multiple HDAC enzymes have been used clinically to treat a number of solid and hematological malignancies. HDACi are also currently being studied for their efficacy in non-malignant diseases, including pathologic bone loss, but this has necessitated a better understanding of the roles of individual HDAC enzymes, particularly the eleven zinc-containing isozymes. Selective isozyme-specific inhibitors currently being developed against class I HDACs (1, 2, 3 and 8) and class II HDACs (4, 5, 6, 7, 9 and 10) will be valuable tools for elucidating the roles played by individual HDACs in different physiological and pathological settings. Isozyme-specific HDACi promise to have greater efficacy and reduced side effects, as required for treating chronic disease over extended periods of time. This article reviews the current understanding of roles for individual HDAC isozymes and effects of HDACi on bone cells, (osteoblasts, osteoclasts and osteocytes), in relation to bone remodelling in conditions characterised by pathological bone loss, including periodontitis, rheumatoid arthritis and myeloma bone disease.
Keyword Histone deacetylases (HDAC)
Myeloma bone disease
Rheumatoid arthritis
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collections: HERDC Pre-Audit
Institute for Molecular Bioscience - Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in Thomson Reuters Web of Science Article
Scopus Citation Count Cited 0 times in Scopus Article
Google Scholar Search Google Scholar
Created: Tue, 27 Dec 2016, 10:23:02 EST by System User on behalf of Learning and Research Services (UQ Library)